Christopher Shaw

Title: Christopher Shaw: Innovator in Peptide Research

Introduction

Christopher Shaw is a notable inventor based in Belfast, GB. He has made significant contributions to the field of peptide research, particularly in the development of compounds that exhibit selective actions on smooth muscle. With a total of 2 patents, his work has implications for the treatment of cardiovascular diseases.

Latest Patents

Shaw's latest patents include a focus on peptides, specifically an N-terminal hexapeptide fragment of maximakinin, known as QUB 698.8. This compound demonstrates potent tissue-selective actions on smooth muscle. It shows a high degree of selectivity for arterial smooth muscle over small intestinal smooth muscle, leading to significant relaxation of arterial smooth muscle while causing less potent contraction of ileal smooth muscle. The potential applications of this peptide include treatment for diseases of the cardiovascular system and promotion of angiogenesis.

Career Highlights

Christopher Shaw is affiliated with The Queen's University of Belfast, where he conducts his research and development work. His innovative approach to peptide research has positioned him as a key figure in the scientific community.

Collaborations

Shaw collaborates with esteemed colleagues such as Tianbao Chen and Martin O'Rourke, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Christopher Shaw's work in peptide research exemplifies the intersection of innovation and practical application in medicine. His contributions are paving the way for advancements in the treatment of cardiovascular diseases.